45th week of 2020 patent applcation highlights part 9 |
Patent application number | Title | Published |
20200345743 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS - This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders. | 2020-11-05 |
20200345744 | TREATMENT OF TACHYCARDIA - The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome. | 2020-11-05 |
20200345745 | KYNURENINE 3-MONOOXYGENASE (KMO) INHIBITORS, AND USES AND COMPOSITIONS THEREOF - There is provided compounds of formula (I) or pharmaceutically-acceptable salts thereof, wherein: L, X, R | 2020-11-05 |
20200345746 | Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patents - The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the prevention of Alzheimer's disease in a patient at risk of developing clinical symptoms of Alzheimer's disease, and in particular, wherein the patient at risk of developing clinical symptoms of Alzheimer's disease carries one or two copies of the ApoE4 allele. | 2020-11-05 |
20200345747 | USE OF FENOLDOPAM FOR THE TREATMENT OF HEMOLYTIC UREMIC SYNDROME - The present invention relates to the use of fenoldopam, its salts and/or derivatives for the treatment of hemolytic uremic syndrome (HUS), preferably in the form due to infection from Shiga-like toxin-producing | 2020-11-05 |
20200345748 | METHODS FOR TREATING PAIN ASSOCIATED WITH SICKLE CELL DISEASE - A method for treating pain experienced by patients with sickle cell disease. | 2020-11-05 |
20200345749 | BICYCLIC SULFONAMIDES - Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formulae (I) and/or (II), or a pharmaceutically acceptable salt of any of the foregoing. | 2020-11-05 |
20200345750 | OIL-IN-WATER METHOD FOR MAKING POLYMERIC IMPLANTS CONTAINING A HYPOTENSIVE LIPID - Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration. | 2020-11-05 |
20200345751 | FULVESTRANT COMPOSITIONS AND METHOD OF USE - Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes. | 2020-11-05 |
20200345752 | APPLICATIONS OF DESOGESTREL IN THE PREPARATION OF ANTI-COLON CANCER/BREAST CANCER ER-NEGATIVE AH RECEPTOR-POSITIVE PRODUCTS - This invention discloses applications of desogestrel in the preparation of anti-colon cancer/breast cancer ER-negative Ah receptor-positive products. This invention provides applications for desogestrel in the preparation of products to treat colon cancer and/or breast cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug desogestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that desogestrel has a new use as an anti-colon cancer medication, thus achieving a new purpose for an old drug. | 2020-11-05 |
20200345753 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER - The present disclosure provides methods, compositions, and kits for treating cancer using a combination of L-rhamnose and a leucine aminopeptidase inhibitor. | 2020-11-05 |
20200345754 | METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS - Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period. | 2020-11-05 |
20200345755 | Treatment Regimens - The invention relates to 5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, in particular by intravenous infusion for a continuous period of up to 10 hours. The invention also relates to methods of treating cancer by administration of NUC-3373 to particular sub-groups of cancer patient. The invention further relates to methods for selecting a patient for treatment with NUC-3373. | 2020-11-05 |
20200345756 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY - It is disclosed herein that RPE degeneration in human cell culture and in mouse models is driven by a non-canonical inflammasome pathway that results in activation of caspase-4 (also known as caspase-11 in mouse) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-β (IFN-β) production and gasdermin D-dependent interleukin-18 (IL-18) secretion. Reduction of DICER1 or accumulation of Alu RNA triggers cytosolic escape of mitochondrial DNA, which engages cGAS. Collectively, these data highlight an unexpected role for cGAS in responding to mobile element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial damage-induced NLRP3 activation, and expand the immune sensing repertoire of cGAS and caspase-4 to non-infectious human disease. Coupled with the unexpected result that caspase-4, gasdermin D, IFN-β, and cGAS are elevated in the RPE of human eyes with geographic atrophy, these findings also identify new targets for a major cause of blindness. | 2020-11-05 |
20200345757 | USE OF SPECIFIC SIRNA AGAINST PROTEIN S FOR THE TREATMENT OF HEMOPHILIA - The invention provides an siRNA against protein S for use in a method of treatment of hemophilia. Also within the scope of the present invention is a method for treating hemophilia in a patient in need thereof, comprising administering to the patient a molecule comprising a siRNA according to the invention, and a dosage form for the prevention or treatment of hemophilia, comprising a molecule comprising a siRNA according to the invention. | 2020-11-05 |
20200345758 | SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the serum amyloid P component (APCS) gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of an APCS gene and to treat subjects having an APCS-associated disease, e.g., amyloidosis, Alzheimer's disease or coronary atherosclerotic heart disease. | 2020-11-05 |
20200345759 | METHODS OF TREATING GALECTIN-3 DEPENDENT DISORDERS - A therapeutic composition includes a polysaccharide, isolated from a member of the genus | 2020-11-05 |
20200345760 | STABILIZED AQUEOUS COMPOSITION COMPRISING CHONDROITIN SULFATE AND HYALURONIC ACID - The present invention relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, and a pharmaceutically acceptable carrier, and which can be stored at room temperature. | 2020-11-05 |
20200345761 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DEMENTIA - Provided is a preventive and/or therapeutic agent for dementia. The preventive and/or therapeutic agent for dementia comprises hydrogen gas as an active ingredient. | 2020-11-05 |
20200345762 | METHOD AND SYSTEM FOR PROVIDING PERITONEAL DIALYSIS FLUIDS WITH VARYING SODIUM CONCENTRATIONS - Methods are provided for preparing a ready-to-use peritoneal dialysis fluid for peritoneal dialysis of a patient. The methods comprise mixing, immediately before administration to the patient, appropriate amounts of at least a first concentrate and a second concentrate with an appropriate amount of water to form a ready-to-use dialysis fluid. The first concentrate comprises glucose and has a pH of between 1.5 and 4; and the second concentrate comprises a physiologically acceptable buffer and sodium ions, and has a pH of between 5.0 and 9.0. The ready-to-use dialysis fluid has a sodium ion concentration of about 110 mM to about 145 mM and an osmolality of about 0.20 to about 0.50 Osm/kg. | 2020-11-05 |
20200345763 | COMPOSITIONS OF AMORPHOUS CALCIUM CARBONATE FOR INHALATION, SUBLINGUAL OR BUCCAL ADMINISTRATION - The present invention provides compositions comprising amorphous calcium carbonate (ACC), suitable to being administered by inhalation, and methods for their use in treating ACC-responsive diseases and conditions. Further provided are ACC compositions suitable for buccal or sublingual administration. | 2020-11-05 |
20200345764 | STABILIZED AMORPHOUS CALCIUM CARBONATE FOR TREATMENT OF NEUROLOGICAL, MUSCULAR AND INFERTILITY DISEASES OR CONDITIONS - Stabilized amorphous calcium carbonate (ACC) for treatment of several neurological, muscular and infertility diseases and conditions is provided. In particular, the stabilized ACC may be used in the treatment of axonal defects and muscular dystrophy. In addition, provided are improved methods used in assistant reproductive technology. Examples of such methods are in vitro fertilization and improvement of sperm quality. The improved IVF method, for example, comprises addition of the stabilized ACC to the cell culture medium in which the stages of fertilization and embryo development occurs. | 2020-11-05 |
20200345765 | IRON-POLYSACCHARIDE COMPLEXES AND METHODS FOR THE PREPARATION THEREOF - The present invention generally relates to iron-polysaccharide (polydextrose) complexes and methods for the preparation thereof. In particular, the present invention relates to iron-polydextrose complexes and methods for the preparation thereof. The inventive complexes are suitable for use in various compositions, including particulate compositions that may be incorporated in various forms of administration, including tablets, capsules, and intravenous formulations. The complexes and compositions of the present invention are suitable for use in the treatment of iron deficient anemia. Advantageously, in addition to providing iron supplementation the complexes and compositions of the present invention provide certain advantages based on the presence of polydextrose (e.g., its low glycemic index and high fiber content). | 2020-11-05 |
20200345766 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2020-11-05 |
20200345767 | Fast Acting Inhibitor of Gastric Acid Secretion - The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti- | 2020-11-05 |
20200345768 | ZINC PICOLINATE, MAGNESIUM PICOLINATE AND SELENIUM METHIONINE COMPOSITIONS AND METHODS OF USE - The present application relates to zinc picolinate, magnesium picolinate and selenium methionine compositions and methods of use. The methods and compositions disclosed herein are particularly useful for optimizing antioxidant and hormone levels and improving bone mineral density. | 2020-11-05 |
20200345769 | NUTRITIONAL SUPPLEMENT FOR GROWTH ENHANCEMENT - Provided are nutritional supplements designed for enhancing the growth, particularly the linear growth, of pre-pubertal children with a stature measure short compared to the norm. The nutritional composition includes an energy source, arginine and a combination of micronutrients. | 2020-11-05 |
20200345770 | Combination Therapy for Treatment of Leukemia - The present invention relates to the treatment of leukemia, (e.g. acute myeloid leukemia, AML) using a triple combination of: arsenic trioxide; iron; and an artemisinin, such as artesunate. | 2020-11-05 |
20200345771 | INGESTIBLE COMPOSITION HAVING HYDROGEN PEROXIDE WITH AN INCREASED HALF-LIFE - The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target. thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target. | 2020-11-05 |
20200345772 | METHODS AND COMPOSITIONS TO MODULATE HAIR GROWTH - Embodiments of the methods and compositions provided herein relate to inducing hair growth in a subject. Some embodiments include screening for agents to modulate hair growth. | 2020-11-05 |
20200345773 | ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF - The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid. | 2020-11-05 |
20200345774 | ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF - The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid. | 2020-11-05 |
20200345775 | MSC-EXPRESSED IMMUNOMODULATORS IN COMBINATION WITH CAR-T FOR CANCER THERAPY - This technology describes novel cell based combined therapeutic modalities that induces mechanism based tumor cell killing in a broad spectrum of sensitive and resistant tumors. These new agents are tumor specific and target a broad spectrum of solid tumors. | 2020-11-05 |
20200345776 | CELL - The present invention relates to an engineered cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) one or more engineered polynucleotides which encode one or more enzymes which are capable of synthesising a therapeutic small molecule when expressed in combination in the cell. | 2020-11-05 |
20200345777 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to | 2020-11-05 |
20200345778 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN CARS AND METHODS OF USE THEREOF - The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody. | 2020-11-05 |
20200345779 | COMPOSITIONS AND METHODS FOR TARGETING CLEC12A-EXPRESSING CANCERS - Disclosed are compositions and methods for targeted treatment of CLEC12A-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CLEC12A-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CLEC12A-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CLEC12A-expressing malignant cells. | 2020-11-05 |
20200345780 | MULTILAYERED BLOOD PRODUCT - A blood product ( | 2020-11-05 |
20200345781 | MEDICINE FOR TISSUE REGENERATION, AND PREPARATION METHOD THEREFOR - The present invention relates to a cell-based medicine comprising mesenchymal stem cells, and a method for producing the same. More specifically, the present invention relates to:
| 2020-11-05 |
20200345782 | STEM CELL SUBPOPULATIONS WITH DIFFERENTIAL GSTT1 EXPRESSION OR GENOTYPE - A method for providing a sub-population of stem cell or plurality of stem cells by determining or modulating GSTT1 expression level or genotype is disclosed together with uses of the stem cells. | 2020-11-05 |
20200345783 | COMPOSITION USED FOR THERAPEUTIC TREATMENT OF SKIN DISEASE - The present invention provides an excellent composition for therapeutically treating a skin disease (e.g., a drug, a quasi-drug or a cosmetic). The composition for therapeutically treating a skin disease according to the present invention contains exosomes secreted from stem cells (for example, adipose-derived stem cells), in which the stem cells contain drug-encapsulating nanoparticles comprising a drug (for example, statin, estrogen, retinoic acid and ascorbic acid) encapsulated in nanoparticles containing a bioabsorbable polymer. | 2020-11-05 |
20200345784 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE, AND CELL MASS THEREOF - The present invention aims to provide a method for efficiently producing a cell mass containing pituitary tissue from pluripotent stem cells. A method for producing a cell mass containing pituitary tissue, including the following steps (1) and (2): | 2020-11-05 |
20200345785 | PHENOTYPE PROFILE OF HUMAN RETINAL PROGENITOR CELLS - The present invention relates to substantially homogenous populations of human retinal progenitor cells having the following positive surface markers: SSEA4, CD73, PTK7 and PSA-NCAM. The invention also relates to method for preparing such substantially homogeneous cell populations from human tissue using cell sorting techniques. | 2020-11-05 |
20200345786 | DIRECT REPROGRAMMING OF CELLS TO CARDIAC MYOCYTE FATE - A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts. | 2020-11-05 |
20200345787 | CAMEL HUMP-OIL BASED HERBAL COMPOSITIONS AND METHOD OF MAKING THE SAME - The embodiments herein provide camel hump oil based herbal compositions and methods for preparing these compositions for treatment of a plurality of diseases such as dermatological conditions, musculoskeletal conditions and hair conditions. The embodiments herein also provide a method of extraction of camel hump oil from a camel hump and a method of de-odorizing the extracted camel hump. The camel hump-oil based herbal composition comprises camel hump oil, a herbal oil extract, a curing agent and a plurality of additives. The camel hump oil based composition is topically applied. | 2020-11-05 |
20200345788 | HUMAN HEPATOCYTES AND USES THEREOF - Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein. | 2020-11-05 |
20200345789 | PRODUCTION METHOD FOR IPS CELL-DERIVED POPULATION OF GENETICALLY DIVERSE T CELLS - [Problem] To provide a method for producing a population of genetically diverse regenerated T cells via iPS cells, and to provide said population of regenerated T cells. | 2020-11-05 |
20200345790 | PHARMACEUTICAL ORAL FORMULATION COMPRISING BACTERIA - The present invention relates to a pharmaceutical oral formulation for use in the administration of at least two bacteria derived from fecal microbiota to mammals for the treatment and/or prevention of dysbiosis and associated pathologies. The pharmaceutical oral formulation is encapsulated mixture of at least two bacteria derived from fecal microbiota wherein the capsules are coated in a pH responsive polymer composition comprising:
| 2020-11-05 |
20200345791 | Probiotic Bacterial Strains That Produce Short Chain Fatty Acids And Compositions Comprising Same - Disclosed herein are probiotic bacterial strains or species that produce short chain fatty acids (SCFA), such as butyrate, and compositions comprising the same. The bacterial strains or compositions prepared thereby are used in preparing food, supplements, compositions, and other consumables to provide health benefits, including therapeutic applications, for a variety of disorders, including metabolic, immune, intestinal, and inflammatory disorders. Thus, also disclosed herein are methods of treating a subject suffering from a disorder, such as a metabolic disorder, an immune disorder, an intestinal disorder, or an inflammatory disorder with a composition comprising the probiotic bacterial strains or species disclosed herein. Uses of a bacterial strain or species and a composition comprising them provided in a nutritional product or medicament to improve health or prevent or treat a variety of disorders in a subject are also disclosed. | 2020-11-05 |
20200345792 | Synergistic Bacterial Compositions and Methods of Production and Use Thereof - Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human. | 2020-11-05 |
20200345793 | GENE EXPRESSION SYSTEM FOR PROBIOTIC MICROORGANISMS - Provided herein are recombinant microorganisms that express a subject polypeptide. Microorganisms can comprise an expression construct comprising a flagellin promoter operatively linked with a heterologous nucleotide sequence encoding the subject polypeptide. The flagellin promoter sequence can comprise a genetic modification that reduces CsrA inhibition of translation. Microorganisms also can comprise a genetic modification that reduces FlgM inhibition of SigD initiation of transcription. The target polypeptide can be an aldehyde dehydrogenase. Such microorganisms are useful in the treatment of alcohol hangover. | 2020-11-05 |
20200345794 | COMPOSITION FOR IMPROVING THE WELL-BEING OF ANIMALS - A method for the prevention or treatment of pathogens affecting the health of livestock animals, which includes the administration to the livestock animals a composition having at least one bacterial strain of the genus | 2020-11-05 |
20200345795 | MODULATION OF INTESTINAL MICROBIOTA IN PRE-DIABETES AND TYPE 2 DIABETES - Provided herein are methods for modulating the intestinal microbial profile and for reducing intestinal dysbiosis in type 2 diabetic or pre-diabetic subjects, comprising administering metformin or a derivative or salt thereof and one or more probiotic microorganisms selected from | 2020-11-05 |
20200345796 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS - The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions. | 2020-11-05 |
20200345797 | LACTIC ACID BACTERIA AND ANTI-INFLAMMATORY METHOD THEREOF | 2020-11-05 |
20200345798 | LACTOBACILLUS HAVING ANTIMICROBIAL EFFECT ON GARDNERELLA VAGINALIS AND CANDIDA ALBICANS - The present invention relates to a | 2020-11-05 |
20200345799 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES - Disclosed herein are compositions and methods for using human-derived | 2020-11-05 |
20200345800 | MEDICATION FOR INFLUENZA - A medication for preventing or treating influenza, said medication including an inactivated influenza virus or a recombinant vaccinia virus that includes, within the genome of the vaccinia virus DIs strain, an expression promoter and all or a portion of DNA coding for an influenza virus-derived protein. | 2020-11-05 |
20200345801 | BOSWELLIC ACID EXTRACTION - The invention is directed to an improved method of extracting boswellic acid from | 2020-11-05 |
20200345802 | COMPOSITION FOR PREVENTING OR TREATING GLIOBLASTOMA COMPRISING PLATYCODON GRANDIFLORUM A. DE CANDOLLE, SCUTELLARIA BAICALENSIS, PHELLODENDRON AMURENSE RUPRECHT OR RUBUS COREANUS - The present invention relates to an extract of at least any one selected from the group consisting of | 2020-11-05 |
20200345803 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME - The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof. | 2020-11-05 |
20200345804 | NOVEL AGENTS TARGETING INHIBITOR OF APOPTOSIS PROTEINS - Disclosed herein, inter alia, are methods of use and composition of novel inhibitors that target the Smac binding site of a variety of inhibitor of apoptosis proteins that contain a Bir domain, including XIAP, cIAP1, cIAP2, or other IAP proteins. | 2020-11-05 |
20200345805 | COMPOSITIONS AND METHODS USEABLE FOR TREATMENT OF DRY EYE - Compositions and methods for treating Dry Eye in a human or non-human animal subject wherein an effective amount of a pharmaceutical composition comprising an anti-integrin peptide is administered to an eye of the subject. The anti-integrin peptide may comprise a peptide which causes at least one effect selected from: reduced expression of the Complement 3 Receptor (Integrin αMβ2); reduced leucocyte adhesion; and reduced trans-endothelial leucocyte migration. The peptide may comprises Risuteganib. | 2020-11-05 |
20200345806 | METHOD AND COMPOSITION FOR SYNCHRONIZING TIME OF INSEMINATON - Methods and compositions for synchronizing the time of insemination in swine are described. More particularly, methods are described for synchronizing the time of insemination by administration of a composition comprising a hormone, wherein the swine is inseminated only one time after administration of the hormone, and wherein there is no heat detection. | 2020-11-05 |
20200345807 | PSMA-TARGETING AMANITIN CONJUGATES - The invention relates to a PSMA-targeting conjugate comprising (a) an amatoxin; (b) a small molecule PSMA-targeting moiety; and (c) optionally a linker linking said amatoxin and said small molecule PSMA-targeting moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate. | 2020-11-05 |
20200345808 | NOVEL PHARMACOLOGICAL THERAPY FOR NEURONOPATHIC GAUCHER DISEASE - The instant disclosure relates to methods and compositions for the treatment of Gaucher disease, particularly type II and III neuronopathic Gaucher disease (nGD). The methods include the step of administering to an individual in need thereof an effective amount of a ryanodine receptor inhibitor or a pharmaceutically acceptable salt thereof. | 2020-11-05 |
20200345809 | IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINS - This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells. | 2020-11-05 |
20200345810 | USE OF ALPHA-1-MICROGLOBULIN FOR PROTECTION OF BONE MARROW CELLS - The present invention relates to alpha-1-microglobulin (A1M) for use in the protection of bone marrow cells in a subject. | 2020-11-05 |
20200345811 | METHODS AND COMPOSITIONS FOR MODULATING MYOFIBROBLAST ACTIVITIES - The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof. | 2020-11-05 |
20200345812 | METHODS OF NEUROPROTECTION INVOLVING MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR AGONISTS - The present invention provides methods for preventing, attenuating neuronal damage or stimulating neuronal repair prior or following central nervous system injury. | 2020-11-05 |
20200345813 | Compositions and Methods for the Systemic Treatment of Arthritis - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. | 2020-11-05 |
20200345814 | HUMAN-DERIVED RECOMBINANT FSH FOR CONTROLLED OVARIAN STIMULATION - Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility. | 2020-11-05 |
20200345815 | TYPE I DIABETES THERAPY - The present invention relates to novel methods and therapies for treating, preventing or delaying the onset of type 1 diabetes. In one aspect, the invention provides a method of preventing, delaying the onset of, or delaying the progression of, type 1 diabetes (T1D) in an individual, the method comprising providing in the individual an anti-inflammatory compound; and a pancreatic autoantigen or a derivative or variant thereof; thereby preventing, delaying the onset of, or delaying the progression of, T1D in the individual. | 2020-11-05 |
20200345816 | FORMULATION WITH CANNABINOIDS - A food supplement comprising a therapeutically effective amount of a composition is described. The composition includes hydrolyzed collagen, hyaluronic acid, ascorbic acid, and glucosamine hydrochloride. The composition may also include a cannabinoid or prodrug, vitamin C, vitamin D, and/or vitamin E. The therapeutically effective amount of the composition is effective in alleviating at least one symptom of a degenerative joint disease in a human or may be used for the prophylaxis of the degenerative joint disease in the human. The at least one symptom of the degenerative joint disease in the human includes joint pain and mobility pain. | 2020-11-05 |
20200345817 | GLUCOSE OXIDASE COMPOSITIONS AS A NEONATE ANTICONVULSANT - Neonatal seizure is different from adult seizure, and many anti epileptic drugs that are effective in adults often fail to treat neonatal seizure. Gluconic acid, a natural organic acid enriched in fruits and honey, and the glucose oxidase enzyme, is shown herein to potently inhibit neonatal epilepsy both in vitro and in vivo. Sodium gluconate is shown to inhibit epileptiform burst activity in cell cultures and protect neurons from kainic acid-induced cell death. Sodium gluconate also inhibited epileptiform burst activity in brain slices in a manner that was much more potent in neonatal animals than in older animals. Consistently, in vivo EEC recordings also revealed that sodium gluconate inhibited the epileptic seizure activity in a manner that was much more potent in neonates than in adult animals. Mechanistically, sodium gluconate inhibits voltage-dependent CLC-3 C1 | 2020-11-05 |
20200345818 | ENZYMES AND METHODS FOR CLEAVING N-GLYCANS FROM GLYCOPROTEINS - Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity. | 2020-11-05 |
20200345819 | Compositions and Methods for Safe Treatment of Rhinitis - Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis. | 2020-11-05 |
20200345820 | COMBINATION THERAPIES FOR CANCER - Disclosed herein are methods for treating cancer by administering to a subject a composition comprising a bacteriophage expressing a fragment of human aspartate β-hydroxylase (ASPH) and an immune checkpoint protein inhibitor. | 2020-11-05 |
20200345821 | METHODS AND COMPOSITIONS FOR REDUCING GROWTH, MIGRATION AND INVASIVENESS OF BRAIN CANCER STEM CELLS AND IMPROVING SURVIVAL OF PATIENTS WITH BRAIN TUMORS - The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells. | 2020-11-05 |
20200345822 | WHOLE-CELL TUMOR VACCINE BASED ON PRINCIPLE OF EXTRACELLULAR TRAP AND METHOD OF MAKING SAME - Disclosed are a whole-cell tumor vaccine based on the principle of extracellular traps and a method of making the same, where a CpG ODN network similar to the extracellular trap in structure is formed on the tumor cell surface. The tumor cells are coated with a histone and CpG ODN to form the CpG ODN-coated tumor cells, which are inactivated to produce the whole-cell tumor vaccine. The vaccine of the invention, after injected to tumor model mice, can induce the occurrence of effective immune response to achieve the effective treatment for tumors. | 2020-11-05 |
20200345823 | TREATMENT OF CNS LYMPHOMA AND SYSTEMIC LYMPHOMA WITH INTRACEREBROVENTRICULARLY ADMINISTERED CD19 CAR - An improved method of treating cancers CD19 CAR T cells by administering the CD19 CAR T cells to the central nervous system, e.g., by intracerebroventricular administration, is described. | 2020-11-05 |
20200345824 | VACCINE - Vaccines and methods are for immunization against | 2020-11-05 |
20200345825 | FORMULATION OF FISH VACCINE BASED ON LIPIDIC NANOVESICLES, IN PARTICULAR, A PROTEOLIPOSOME OR COCHLEATE, WITH ACTIVITY AGAINST THE SALMONID RICKETTSIAL SYNDROME (SRS) - The invention relates to aquaculture. In particular, it relates to immunisation in fish farming. More particularly, the present invention relates to a vaccine formulation for fish, based on lipid nanovesicles with activity. Even more particularly, the present invention relates to a vaccine formulation for fish, based on lipid nanovesicles, especially a proteoliposome, with activity against salmon rickettsial syndrome (SRS) | 2020-11-05 |
20200345826 | METHODS AND COMPOSITIONS FOR TREATING GLIOMA AND MEDULLOBLASTOMA BRAIN TUMORS USING THE ZIKA VIRUS - In one embodiment, the present invention is a method of treating glioma and medulloblastoma brain tumors using the Zika virus and a tumor vaccine. | 2020-11-05 |
20200345827 | METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS - The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject. | 2020-11-05 |
20200345828 | NOROVIRUS VACCINE - A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections. | 2020-11-05 |
20200345829 | IMMUNOGENIC RSV POLYPEPTIDES - This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39. | 2020-11-05 |
20200345830 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME - Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Merkel Cell Polyomavirus (MCV) T antigen. Immunomodulatory methods and methods of inducing an immune response against MCV are disclosed. Method of treating infection by MCV and methods of treating or preventing Merkel Cell Carcinoma associated with MCV are disclosed. Modified consensus MCV T antigens are disclosed. | 2020-11-05 |
20200345831 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN - The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal. | 2020-11-05 |
20200345832 | RABIES VIRUS VACCINE - The present invention provides a vaccine for rabies virus and methods of making and using the vaccine alone, or in combinations with other protective agents. | 2020-11-05 |
20200345833 | REV-DEPENDENT LENTIVIRAL VACCINE PARTICLES FOR REDUCING VIRAL REBOUND AND VIRAL RESERVOIRS IN VIVO - Persistence of HIV in anatomic sanctuary sites such as the brain prevents viral eradication. Although combination antiretroviral therapy (cART) inhibits viral replication to undetectable level by standard clinical assay, it does not selectively eliminate virus reservoirs. To target HIV reservoirs, the present inventor developed an HIV Rev-dependent lentiviral vector carrying a series of therapeutic genes, such as diphtheria toxin, anthrolysin O from | 2020-11-05 |
20200345834 | METHODS OF MANUFACTURING AN IMMUNOGENIC COMPOSITION COMPRISING A RECOMBINANT PROTEIN - The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity. | 2020-11-05 |
20200345835 | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS - The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease. | 2020-11-05 |
20200345836 | VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS - The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions. | 2020-11-05 |
20200345837 | COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSE - The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided. | 2020-11-05 |
20200345838 | A Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein - Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof. | 2020-11-05 |
20200345839 | Recombinant hypoallergenic Equ c 1 polypeptides for use in the immunotherapy of horse allergy - The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen. | 2020-11-05 |
20200345840 | QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF - Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof. | 2020-11-05 |
20200345841 | COMPOSITIONS AND USES - The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant. | 2020-11-05 |
20200345842 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual. | 2020-11-05 |